Elevated expression of cyclooxygenase-2 is a negative prognostic factor for disease free survival and overall survival in patients with breast carcinoma

Cancer

Volumn 97, Issue 12, 2003, Pages 2978-2987

  Denkert, Carsten ^a   Winzer, Klaus Jürgen ^a   Müller, Berit Maria ^a   Weichert, Wilko ^a   Pest, Sören ^b   Köbel, Martin ^a   Kristiansen, Glen ^a   Reles, Angela ^a   Siegert, Antje ^a   Guski, Hans ^a   Hauptmann, Steffen ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b TECHNISCHE UNIVERSITÄT BERLIN   (Germany)

Author keywords

Breast carcinoma; Cyclooxygenase 1; Cyclooxygenase 2; Prognostic factor

Indexed keywords

CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; ESTROGEN RECEPTOR;

ADULT; AGED; ARTICLE; BREAST CARCINOMA; CANCER GROWTH; CANCER INVASION; CANCER RISK; CANCER SURVIVAL; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; SURVIVAL RATE; TUMOR VOLUME;

ADULT; BREAST NEOPLASMS; CARCINOMA; COHORT STUDIES; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; ISOENZYMES; LYMPHATIC METASTASIS; MEMBRANE PROTEINS; MIDDLE AGED; PROGNOSIS; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; SURVIVAL ANALYSIS;

EID: 0038010530     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.11437     Document Type: Article

References (21)

1. Jemal A, Thomas A, Murray T, Thun M. Cancer statistics, 2002. CA Cancer J Clin. 2002;52:23-47.
2. National Institutes of Health Consensus Development Panel. National Institutes of Health consensus development conference statement: adjuvant therapy for breast cancer. J Natl Cancer Inst. 2001;93:979-989.
3. Goldhirsch A, Glick JH, Gelber RD. Meeting highlights: international consensus panel on the treatment of primary breast cancer. J Natl Cancer Inst. 1998;90:1601-1608.
4. Khuder SA, Mutgi AB. Breast cancer and NSAID use: a metaanalysis. Br J Cancer. 2001;84:1188-1192.
5. Howe LR, Subbaramaiah K, Brown AMC. Cyclooxygenase-2: a target for the prevention and treatment of breast cancer. Endocrine Relat Cancer. 2001;8:97-114.
6. Parret ML, Harris RL, Joarder FS, et al. Cyclooxygenae-2 gene expression in human breast cancer. Int J Oncol. 1997; 10:503-508.
7. Hwang D, Scollard D, Byrne J, et al. Expression of cyclooxygenase-1 and cyclooxygenase-2 in human breast cancer. J Natl Cancer Inst. 1998;90:455-460.
8. Soslow RA, Dannenberg AJ, Rush D, et al. COX-2 is expressed in human pulmonary, colonic and mammary tumors. Cancer. 2000;89:2637-2645.
9. Half E, Tang XM, Gwyn K, et al. Cyclooxygenase-2 expression in human breast cancers and adjacent ductal carcinoma in situ. Cancer Res. 2002;62:1676-1681.
10. Ristimäki A, Sivula A, Lundin J, et al. Prognostic significance of elevated cyclooxygenase-2 expression in breast cancer. Cancer Res. 2002;62:632-635.
11. Costa C, Soares R, Reis-Filho JS, et al. Cyclooxygenase 2 expression is associated with angiogenesis and lymph node metastasis in human breast cancer. J Clin Pathol. 2002;55: 429-434.
12. Elston CW, Ellis IO. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology. 1991;5:403-410.
13. Sobin LH, Wittekind C. TNM classification of malignant tumours. 6th edition. New York: Wiley-Liss, Inc., 2002.
14. Shirahama T, Arima J, Akiba S, et al. Relation between cyclooxygenase-2 expression and tumor invasiveness and patient survival in transitional cell carcinoma of the urinary bladder. Cancer. 2001;92:188-193.
15. Remmele W, Stegner HE. Recommendation for uniform definition of an immunoreactive score (IRS) for immunohistochemical estrogen receptor detection (ER-ICA) in breast cancer tissue. Pathologe. 1987;3:138-140.
16. Shono T, Tofilon PJ, Bruner JM, et al. Cyclooxygenase-2 expression in human gliomas: prognostic significance and molecular correlations. Cancer Res. 2001;61:4375-4381.
17. Masunaga R, Kohno H, Dhar DK, et al. Cyclooxygenase-2 expression correlated with tumor neovascularisation and prognosis in human colorectal carcinoma patients. Clin Cancer Res. 2000;6:4046-4068.
18. McCormick DL, Moon RC. Inhibition of mammary carcinogenesis by flurbiprofen, a non-steroidal anti-inflammatory agent. Br J Cancer. 1983;48:859-861.
19. Harris RE, Alshafie GA, Abou-Issa H, et al. Chemoprevention of breast cancer in rats by celecoxib, a cyclooxygenase inhibitor. Cancer Res. 2000;60:2101-2103.
20. Alshafie GA, Abou-Issa H, Seibert K, et al. Chemotherapeutic evaluation of celecoxib, a cyclooxygenase-2 inhibitor, in rats mammary tumor model. Oncol Rep. 2000;7: 1377-1381.
21. Vadlamudi R, Mandal M, Adam L, et al. Regulation of cyclooxygenase-2 pathway by HER2 receptor. Oncogene. 1999;18: 305-314.